Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diamyd for Latent Autoimmune Diabetes in Adults (LADA)
2004-001998-25Phase 2Completed
- Sponsor
- Diamyd Medical
- Start
- Jul 2004
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in latent autoimmune diabetes in adults (LADA) comparing Diamyd with Placebo (2 arms). Primary endpoints: Long-term safety, Development of diabetes status (HbA1c) and 3 more. Started Jul 2004; status: completed.
02
Drugs
Diamyd
03
Conditions
latent autoimmune diabetes in adults (LADA)
Beyond the preview
Go deeper on 2004-001998-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001998-25.